Farastuk Bozorgmehr
Farastuk Bozorgmehr, MD is an expert in Oncology at University Hospital Heidelberg (Germany). As of October 2026, ScienceLeadR ranks Farastuk Bozorgmehr in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Farastuk Bozorgmehr has authored 105 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 13 of them ongoing. SLR score: 959 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Radiotherapy - Neurology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 105
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. PMID 42929675 — progression-free survival, disease progression, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, therapeutics | N Engl J Med Top journal | 2026 | 0 |
| Real-World Experience With Multimodal Treatment of Resectable Stage II-III Non-Small Cell Lung Cancer: A Single Institutional Analysis. PMID 42872517 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, combined modality therapy, lung neoplasms, small cell lung carcinoma, neoadjuvant therapy, morbidity, therapeutics, chemotherapy | Int J Cancer | 2026 | 0 |
| Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass). PMID 42710416 — cells, genes, recombination, genetic, lung, poly(adp-ribose) polymerases, homologous recombination, neoplasms, poly adenosine diphosphate ribose, biomarkers, maintenance, lung neoplasms, recombinational dna repair, small cell lung carcinoma, therapeutics, etoposide, carboplatin | Clin Lung Cancer | 2026 | 0 |
| Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients. PMID 42462290 — radiotherapy, cells, lung, brain, retrospective studies, neoplasms, drug therapy, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy | Clin Lung Cancer | 2026 | 0 |
| Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). PMID 42424047 — radiotherapy, cells, lung, safety, lymphocytes, neoplasms, maintenance, immunotherapy, lung neoplasms, small cell lung carcinoma, infections | JAMA Oncol | 2026 | 4 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
13 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| DAREON Lung 1 A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab carboplatin and etoposide treatment with standard chemotherapy 2025-520565-51-00 — cells, lung, neoplasms, multiple chronic conditions, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, etoposide, carboplatin, chemotherapy | Phase 3 | Not yet recruiting | 2026 |
| Study to assess the efficacy and safety of Rina S in participants with non small cell lung cancer 2025-522107-18-00 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma | Phase 2 | Recruiting | 2026 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First line Treatment of PD L1 high Metastatic Non small Cell Lung Cancer 2024-517780-24-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics | Phase 3 | Recruiting | 2025 |
| Randomized open label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with first line locally advanced or metastatic EGFR mutated NSCLC treated with amivantamab lazertinib 2023-505863-35-00 — cells, lung, incidence, neoplasms, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma | Phase 2 | Active not recruiting | 2024 |
| A Phase I II First In Human Clinical Trial to Evaluate the Safety Tolerability and Anti Tumor Activity of IMA402 a Bispecific T Cell Engaging Receptor Molecule (TCER ) targeting PRAME as Monotherapy or in Combination with a Checkpoint Inhibitor in Patients with Recurrent and or Refractory Solid Tumors 2022-503133-54-00 — cells, safety, neoplasms, t-lymphocytes | Phase 1/Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map